
Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Agomab Therapeutics NV raises US$100m in Series C financing
The closed financing round was led by Fidelity Management & Research Company. New investors EQT Life Sciences, Canaan and Dawn Biopharma/KKR, as...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

French team BioAroma awarded with BISC-E 2023 prize
In front of around 200 invited guests, the French team received the cash prize for first place in the BISC-E 2023 competition and a one-year free BIC...

UK publishes £2bn vision for engineering biology
Following extensive engagement with industry and stakeholders, the new "National Vision for Engineering Biology" lays out the government’s...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...